FI118203B - Förfarande för framställning av en farmaceutisk 4-hydroxi-a1-[[[6-(4-fenylbutoxi)hexyl]-amino]metyl]-1,3-bensendimetanols 1-hydroxi-2-naftalenkarboxylat(hydroxinaftoat)salt innehållande dosform - Google Patents
Förfarande för framställning av en farmaceutisk 4-hydroxi-a1-[[[6-(4-fenylbutoxi)hexyl]-amino]metyl]-1,3-bensendimetanols 1-hydroxi-2-naftalenkarboxylat(hydroxinaftoat)salt innehållande dosform Download PDFInfo
- Publication number
- FI118203B FI118203B FI982081A FI982081A FI118203B FI 118203 B FI118203 B FI 118203B FI 982081 A FI982081 A FI 982081A FI 982081 A FI982081 A FI 982081A FI 118203 B FI118203 B FI 118203B
- Authority
- FI
- Finland
- Prior art keywords
- hydroxy
- spherical
- hydroxynaphthoate
- salt
- dosage form
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
- C07C217/02—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C217/04—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
- C07C217/06—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted
- C07C217/08—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted the oxygen atom of the etherified hydroxy group being further bound to an acyclic carbon atom
- C07C217/10—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted the oxygen atom of the etherified hydroxy group being further bound to an acyclic carbon atom to an acyclic carbon atom of a hydrocarbon radical containing six-membered aromatic rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Communicable Diseases (AREA)
- Pulmonology (AREA)
- Oncology (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Polyesters Or Polycarbonates (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Fats And Perfumes (AREA)
- Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
Claims (10)
1. Förfarande för framställning av en farmaceutisk dosform för inhalering och in-bläsning, företrädesvis för skötsel av andningsstörningar, vilken dosform innehäller 5 ett 4-hydroxi-a1-[[[6-(4-fenylbutoxi)hexyl]-amino]metyl]-l,3-bensendimetanols 1-hydroxi-2-naftalenkarboxylat (hydroxinaftoat)salt, kännetecknat därav, att det i förfarandet använda saltet är i form av mikrokristallina sfäriska sammanväxningar, vilka sfäriska sammanväxningarna är fritt rinnande, sköra och mikroniserbara, vilket sait mätäs tili en mikroniserare och mikroniseras för att alstra ett mikroniserat 10 ämne, som uppsamlas och används som en farmaceutisk dosform, som ges genom ’ inhalering eller inbläsning.
2. Förfarande enligt patentkravet 1, kännetecknat därav, att saltet mikroniserats tili en partikelstorlek av 1 -10 pm. 15
3. Förfarande enligt patentkravet 1 eller 2, kännetecknat därav, att mikro-kristallernas sfäriska sammanväxningars genomsnittlig yta-area (här definierad ovan) är 4 - 12 mzg särskilt 6 -10 m2g \ 20
4. Förfarande enligt nägot av patentkraven 1-3, kännetecknat därav, att mikrokristallernas sfäriska sammanväxningars luftade bulkdensitet (här definierad ovan) är 0,2 - 0,5 gml'1, särskilt 0,3 - 0,4 gml'1, • « • · · • · • · • ·· ;\i
5. Förfarande enligt nägot av patentkraven 1 - 4, kännetecknat därav, att * · 25 mikrokristallernas sfäriska sammanväxningars kohesion (här definierad ovan) är 0 - • » 20 %, särskilt 0 - 5 %. * t « ·
6. Förfarande enligt nägot av patentkraven 1 - 5, kännetecknat därav, att mikrokristallernas sfäriska sammanväxningars jämnhetskoefficient (här definierad • · · *. 30 ovan) är 1 - 5, särskilt ca 3. • · ♦ • · · * · * ·«» * · • · T
7. Förfarande enligt nägot av patentkraven 1-6, kännetecknat därav, att *·.·* mikrokristallernas sfäriska sammanväxningars friktionsvinkel (här definierad ovan) • * är 25 - 50°, särskilt 40 - 50°C. 35 118203
8. Förfarande enligt nägot av patentkraven 1 - 7, kännetecknat därav, att mikrokristallernas sfäriska sammanväxningars kompressibilitet (här definierad ovan) är 5 - 25 %, särskilt 8 - 20 %. 5
9. Förfarande enligt nägot av patentkraven 1 - 8, kännetecknat därav, att mikrokristallernas sfäriska sammanväxningarna omfattar var och en tunna kristallina skivor, som är anordnade radiellt runt en central kärna eller ihälighet.
10 ·'.··· • » · · · • · · e · · « · 1 2 3 • · • 1 · • · • · • « · • 1 · • · • 1 • · · • · ··· • · · • · · ·· • ·1 • . ··· / • · ··.. • · · * *·· φ ···· ·1· • • · • · · 2 • · · 3 · • · • ♦ · • · 1 • ·
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB9026005 | 1990-11-29 | ||
| GB909026005A GB9026005D0 (en) | 1990-11-29 | 1990-11-29 | Drug material suitable for micronisation |
| GB9102108 | 1991-11-28 | ||
| PCT/GB1991/002108 WO1992009557A1 (en) | 1990-11-29 | 1991-11-28 | Benzenedimethanol suitable for micronisation |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| FI982081A FI982081A (sv) | 1998-09-28 |
| FI982081A0 FI982081A0 (sv) | 1998-09-28 |
| FI118203B true FI118203B (sv) | 2007-08-31 |
Family
ID=10686212
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FI932422A FI118155B (sv) | 1990-11-29 | 1993-05-27 | Förfarande för framställning av för skötsel av andningsstörningar nyttig 4-hydroxi-alfa1-[[[6-(4-fenylbutoxi)hexyl]-amino]metyl]-1,3-bensendimetanols 1-hydroxi-2-naftalenkarboxylat(hydroxinaftoat)salt |
| FI982081A FI118203B (sv) | 1990-11-29 | 1998-09-28 | Förfarande för framställning av en farmaceutisk 4-hydroxi-a1-[[[6-(4-fenylbutoxi)hexyl]-amino]metyl]-1,3-bensendimetanols 1-hydroxi-2-naftalenkarboxylat(hydroxinaftoat)salt innehållande dosform |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FI932422A FI118155B (sv) | 1990-11-29 | 1993-05-27 | Förfarande för framställning av för skötsel av andningsstörningar nyttig 4-hydroxi-alfa1-[[[6-(4-fenylbutoxi)hexyl]-amino]metyl]-1,3-bensendimetanols 1-hydroxi-2-naftalenkarboxylat(hydroxinaftoat)salt |
Country Status (27)
| Country | Link |
|---|---|
| US (1) | US5380922A (sv) |
| EP (2) | EP0639176B1 (sv) |
| JP (1) | JP3375626B2 (sv) |
| KR (1) | KR100192196B1 (sv) |
| AT (1) | ATE144244T1 (sv) |
| AU (1) | AU644505B2 (sv) |
| BG (1) | BG61340B1 (sv) |
| CA (1) | CA2099586C (sv) |
| CY (1) | CY2009A (sv) |
| CZ (1) | CZ282996B6 (sv) |
| DE (1) | DE69122780T2 (sv) |
| DK (1) | DK0639176T3 (sv) |
| ES (1) | ES2093812T3 (sv) |
| FI (2) | FI118155B (sv) |
| GB (1) | GB9026005D0 (sv) |
| GR (1) | GR3022088T3 (sv) |
| HK (1) | HK78997A (sv) |
| HU (1) | HU218205B (sv) |
| IE (1) | IE914146A1 (sv) |
| OA (2) | OA09861A (sv) |
| PL (2) | PL167976B1 (sv) |
| RU (2) | RU2116293C1 (sv) |
| SG (1) | SG49741A1 (sv) |
| SK (1) | SK281095B6 (sv) |
| TW (1) | TW309425B (sv) |
| WO (1) | WO1992009557A1 (sv) |
| ZA (1) | ZA919401B (sv) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9026005D0 (en) * | 1990-11-29 | 1991-01-16 | Glaxo Group Ltd | Drug material suitable for micronisation |
| AU1229892A (en) * | 1992-02-11 | 1993-09-03 | Glaxo Group Limited | Benzenedimethanol derivative suitable for micronisation |
| US6254882B1 (en) | 1997-09-16 | 2001-07-03 | Sepracor Inc. | Methods and compositions for treating pulmonary disorders using optically pure (S)—salmeterol |
| JP2002541183A (ja) | 1999-04-14 | 2002-12-03 | グラクソ グループ リミテッド | 医薬用エアゾール製剤 |
| AU2001292929A1 (en) | 2000-09-26 | 2002-04-08 | Temple University Of The Commonwealth System Of Higher Education | Analgesic and glucosamine compositions |
| EP2127641A1 (en) | 2008-05-26 | 2009-12-02 | Inke, S.A. | Micronisable form of salmeterol xinafoate |
| KR101100614B1 (ko) | 2010-09-20 | 2011-12-29 | 한국수력원자력 주식회사 | 농축폐액 건조물의 펠렛화 장치 및 방법과 이를 이용한 유리조성개발 방법 |
| WO2016142582A1 (en) * | 2015-03-11 | 2016-09-15 | Fermion Oy | Process for the preparation of crystalline salmeterol and its xinafoate salt |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ZW6584A1 (en) * | 1983-04-18 | 1985-04-17 | Glaxo Group Ltd | Phenethanolamine derivatives |
| GB9026005D0 (en) * | 1990-11-29 | 1991-01-16 | Glaxo Group Ltd | Drug material suitable for micronisation |
-
1990
- 1990-11-29 GB GB909026005A patent/GB9026005D0/en active Pending
-
1991
- 1991-11-28 EP EP92900167A patent/EP0639176B1/en not_active Expired - Lifetime
- 1991-11-28 CA CA002099586A patent/CA2099586C/en not_active Expired - Lifetime
- 1991-11-28 AU AU90402/91A patent/AU644505B2/en not_active Ceased
- 1991-11-28 SG SG1996004594A patent/SG49741A1/en unknown
- 1991-11-28 JP JP50047092A patent/JP3375626B2/ja not_active Expired - Lifetime
- 1991-11-28 WO PCT/GB1991/002108 patent/WO1992009557A1/en active Application Filing
- 1991-11-28 PL PL91299352A patent/PL167976B1/pl unknown
- 1991-11-28 RU RU93040704A patent/RU2116293C1/ru active
- 1991-11-28 ZA ZA919401A patent/ZA919401B/xx unknown
- 1991-11-28 AT AT92900167T patent/ATE144244T1/de not_active IP Right Cessation
- 1991-11-28 HU HU9301568A patent/HU218205B/hu unknown
- 1991-11-28 DK DK92900167.5T patent/DK0639176T3/da active
- 1991-11-28 IE IE414691A patent/IE914146A1/en not_active IP Right Cessation
- 1991-11-28 ES ES92900167T patent/ES2093812T3/es not_active Expired - Lifetime
- 1991-11-28 DE DE69122780T patent/DE69122780T2/de not_active Expired - Lifetime
- 1991-11-28 RU RU97121416/04A patent/RU2197475C2/ru active
- 1991-11-28 CZ CS931019A patent/CZ282996B6/cs not_active IP Right Cessation
- 1991-11-28 PL PL91308211A patent/PL169722B1/pl unknown
- 1991-11-28 SK SK545-93A patent/SK281095B6/sk not_active IP Right Cessation
-
1992
- 1992-05-21 EP EP92304635A patent/EP0571669B1/en not_active Expired - Lifetime
- 1992-05-29 TW TW081104199A patent/TW309425B/zh active
-
1993
- 1993-05-14 US US08/050,298 patent/US5380922A/en not_active Expired - Lifetime
- 1993-05-14 OA OA60370A patent/OA09861A/en unknown
- 1993-05-25 BG BG97767A patent/BG61340B1/bg unknown
- 1993-05-27 FI FI932422A patent/FI118155B/sv not_active IP Right Cessation
- 1993-05-27 KR KR1019930701589A patent/KR100192196B1/ko not_active IP Right Cessation
- 1993-09-24 OA OA60416A patent/OA10024A/en unknown
-
1996
- 1996-12-18 GR GR960403534T patent/GR3022088T3/el unknown
-
1997
- 1997-06-12 HK HK78997A patent/HK78997A/xx not_active IP Right Cessation
-
1998
- 1998-02-20 CY CY200998A patent/CY2009A/xx unknown
- 1998-09-28 FI FI982081A patent/FI118203B/sv not_active IP Right Cessation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FI101296B (sv) | Förfarande för framställning av förenings N-£4-£5-(syklopentyloxikarbo nyl)amino-1-metyl-indol-3-ylmetyl|-3-metoxbensoyl|-2-metylbensensulfon amid kristallin form och pelleller av dem | |
| FI118203B (sv) | Förfarande för framställning av en farmaceutisk 4-hydroxi-a1-[[[6-(4-fenylbutoxi)hexyl]-amino]metyl]-1,3-bensendimetanols 1-hydroxi-2-naftalenkarboxylat(hydroxinaftoat)salt innehållande dosform | |
| KR20070001946A (ko) | 결정성8-히드록시-5[(1ｒ)-1-히드록시-2-[[(1ｒ)-2-(4-메톡시페닐)-1-메틸에틸]아미노]에틸]-2(1ｈ)-퀴놀리논모노하이드로클로라이드 및 그 제조방법 | |
| AP323A (en) | Drug material suitable for micronisation. | |
| EP3468949B1 (en) | Crystalline pharmaceutical co-crystals of glycopyrronium bromide with lactose | |
| WO1993016031A1 (en) | Benzenedimethanol derivative suitable for micronisation | |
| EP2303232B1 (en) | Micronisable form of salmeterol xinafoate | |
| IL101798A (en) | 1-hydroxy-2-naphthalene carboxylate (hydroxynaphthoate) salt of 4-hydroxy- alpha1-[[[6-4-phenylbutoxy) hexyl] amino] methyl]-1,3-benzenedimethanol suitable for micronisation | |
| CN1056974C (zh) | 适宜于微粒化的药物材料的制备方法 | |
| US20020072602A1 (en) | Micronized mirtazapine | |
| EP0361659B1 (en) | Pharmaceutical composition | |
| EP3972974A1 (en) | Stable polymorphic form of 6-fluoro-9-methyl-9h-b-carboline and uses thereof | |
| NZ240788A (en) | 1-hydroxy-2-naphthalene carboxylate salt of 4-hydroxy- alpha 1 | |
| SI9200252A (sl) | Zdravilni material, primeren za mikronizacijo |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Patent granted |
Ref document number: 118203 Country of ref document: FI |
|
| MA | Patent expired |